Biogen no longer under investigation by EU over MS drug patent move
Biogen is no longer under investigation by the European Commission for a potential antitrust breach over extra patent protection related to a multiple sclerosis drug, MLex has learned. The US company...To view the full article, register now.
Already a subscriber? Click here to view full article